Drug intelligence / Profile preview

XiaoLiu Formula

Development stage: Preclinical
Lead developer: Shanxi Provincial Hospital of Traditional Chinese Medicine
Administration: Oral

Overview

XiaoLiu Formula is a Traditional Chinese Medicine (TCM) formula currently under investigation for its efficacy and safety in the treatment of relapsed/refractory Diffuse Large B-cell Lymphoma (DLBCL). It is being studied in combination with a gemcitabine-based regimen. The formula is developed by Chinese medical institutions and is undergoing clinical evaluation for its potential anti-cancer effects.

Other names: 消瘤方Xiao Liu Fang

Targets

HIF1A (Hypoxia-inducible factor 1-alpha)JUN (Transcription factor Jun)MMP9 (Matrix metalloproteinase-9)TP53 (Cellular Tumor Antigen p53 R175H)

Beyond the preview

Go deeper on XiaoLiu Formula.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on XiaoLiu Formula.